To include your compound in the COVID-19 Resource Center, submit it here.

Cabozantinib: SPA submitted

Exelixis submitted a protocol to FDA to request an SPA

Read the full 104 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE